|
|
Analysis
of the proliferative potential of tumor cells after stereotactic radiosurgery
for recurrent astrocytic tumors
Kodera T, Kubota T, Kabuto M, Nakagawa T, Takeuchi H, Arishima H, Sato
K, Kobayashi H, Kitabayashi M, Hirose S
Department of Neurosurgery, Fukui Medical University,
Matsuoka, Fukui 910-1193, Japan
We analyzed the effectiveness of stereotactic radiosurgery (SRS) for
recurrent astrocytic tumors histologically.
Five patients were followed by pathological examination after radiosurgery
treatment of recurrent astrocytic tumors. Histological diagnoses at the time of
the last operation before SRS were Daumas-Duport grade II in two patients and
grade IV (glioblastoma) in three patients.
No histological diagnoses at the time of SRS were identified in any patients.
Contrast enhanced lesions enlarged gradually on magnetic resonance (MR) images
after SRS, and local control by SRS was judged as progressive disease
radiologically in all patients.
Four of five patients received re-operation after SRS, and the other patient
died without re-operation and underwent post-mortem examination.
After SRS, Ki-67 labeling indices (LIs) of recurrent astrocytomas initially
diagnosed as grade II were 2.6% and 1.1%.
These LIs were relatively lower than those of the control group of patients with
recurrent grade II astrocytomas that were not treated by SRS.
Ki-67 LIs of three glioblastomas after SRS were 23.5%, 18.6%, and 17.8%.
These LIs were significantly lower than those before SRS (2.3%, 4.5%, and 0.9%).
In the autopsy case, there was a significant difference between the LI of tumor
cells in the radiosurgically treated region (0.9%) and that in the untreated
region (29.2%).
These results suggest that the proliferative potential of malignant astrocytic
tumors in the radiosurgically treated area is reduced after SRS, and that
radiological enlargement of enhanced lesions on MR images is due to propagation
of the residual tumor cells that were not covered by radiosurgical target volume
or to radiation necrosis.
SRS may be a useful therapeutic tool in multidisciplinary treatment of malignant
gliomas.
PMID:
11149242 [PubMed - indexed for MEDLINE]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11149242&dopt=Abstract |
